drugset / Trial / NCT02593318
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).
Timeline
- Start
- 2015-10
- Primary completion
- 2018-09
- Completion
- 2018-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaloacetate | Unknown | 500 mg | Oral |
| Subject | Oxaloacetate | Unknown | 1000 mg | Oral |